Catalog No. | HB996016 |
---|---|
Description | Coltuximab ravtansine (SAR3419) is an antibody-drug conjugate (ADC) targeting CD19 created by conjugating a derivative of the potent microtubule-acting cytotoxic agent, maytansine, to a version of the anti-CD19 antibody, anti-B4, that was humanized as an IgG1 by variable domain resurfacing. Four different linker-maytansinoid constructs were synthesized (average ∼3.5 maytansinoids/antibody for each) to evaluate the impact of linker-payload design on the activity of the maytansinoid-ADCs targeting CD19. Anti-CD19 humanized monoclonal antibody conjugated to DM4. |
Species reactivity | Human |
Applications | Research Grade Biosimilar |
Host species | Chimeric |
Isotype | IgG1-kappa |
Expression system | Mammalian Cells |
Species | Human |
Clonality | Monoclonal |
Target | CD19, Differentiation antigen CD19, T-cell surface antigen Leu-12, B-lymphocyte antigen CD19, B-lymphocyte surface antigen B4 |
Concentration | 1 mg/ml |
Endotoxin level | Please contact with the lab for this information. |
Purity | >95% as determined by SDS-PAGE. |
Purification | Protein A/G purified from cell culture supernatant. |
Accession | P15391 |
Form | Liquid |
Storage buffer | 0.01M PBS, pH 7.4. |
Stability and Storage | Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term. |
Alternate Names | SAR3419, CAS: 1269764-99-9 |
Note | For research use only. Not suitable for clinical or therapeutic use. |
SEC-HPLC detection for Research Grade Coltuximab.
+33(0)3 90 20 54 70
19 rue de la Haye 67300 Schiltigheim France